九芝堂(000989) - 2020 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2020 was ¥892,992,226.47, a decrease of 4.29% compared to ¥933,028,534.85 in the same period last year[10] - Net profit attributable to shareholders was ¥88,932,629.47, representing a year-on-year increase of 10.43% from ¥80,531,852.88[10] - The net profit after deducting non-recurring gains and losses was ¥86,484,976.00, up 32.55% from ¥65,248,892.96 in the previous year[10] - Basic earnings per share increased by 13.02% to ¥0.1059 from ¥0.0937[10] - Operating income decreased by 4.29% to ¥892.99 million, impacted by a decline in prescription drug sales[24] - Net profit attributable to shareholders increased by 10.43% to ¥88.93 million, driven by growth in OTC product revenue and cost reductions[24] - Operating profit increased to ¥110,225,837.50, up 11.3% from ¥98,909,960.78 in the previous period[65] - Net profit for the current period is ¥88,189,073.69, an increase of 10.4% compared to ¥79,774,177.46 in the previous period[65] - The company reported a total comprehensive income of ¥86,370,363.05, compared to ¥79,774,177.46 in the previous period[68] - Total comprehensive income amounted to CNY 61,700,790.21, compared to CNY 38,604,830.99 in the previous period, reflecting a significant increase[75] Cash Flow - The net cash flow from operating activities decreased by 61.43%, amounting to ¥62,952,065.74 compared to ¥163,197,743.60 in the same period last year[10] - Cash inflow from operating activities totaled CNY 782,884,758.15, down from CNY 926,664,231.15 in the previous period, indicating a decrease of approximately 15.5%[76] - Cash outflow from operating activities totaled CNY 719,932,692.41, down from CNY 763,466,487.55 in the previous period, indicating a decrease of about 5.7%[79] - Cash inflow from investment activities was CNY 711,593,800.57, compared to CNY 585,521,097.59 in the previous period, showing an increase of approximately 21.5%[79] - Net cash flow from investment activities was -CNY 84,954,466.90, an improvement from -CNY 267,269,631.23 in the previous period[79] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,119,566,672.16, an increase of 4.38% from ¥4,904,747,670.66 at the end of the previous year[10] - Current liabilities rose to ¥971,375,060.49, compared to ¥842,699,065.28, indicating an increase of about 15.3%[48] - Total liabilities reached ¥1,041,418,711.82, up from ¥912,970,073.37, reflecting a growth of approximately 14.1%[48] - Owner's equity totaled ¥4,078,147,960.34, an increase from ¥3,991,777,597.29, showing a growth of about 2.2%[51] - Total current assets increased to ¥1,253,218,360.10 from ¥1,078,556,692.25, reflecting a growth of about 16.2%[52] - Total non-current assets decreased slightly to ¥2,348,819,523.92 from ¥2,377,743,494.87, a decline of approximately 1.2%[45] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 39,277[14] - Net assets attributable to shareholders reached ¥4,073,608,594.84, up 2.19% from ¥3,986,459,014.73[10] - The company's retained earnings grew to ¥1,381,369,733.52 from ¥1,292,437,104.05, an increase of about 6.9%[51] Research and Development - Research and development expenses decreased by 26.87% to ¥22.72 million, influenced by project progress[24] - Research and development expenses were ¥6,925,829.02, slightly down from ¥7,601,394.62, indicating a focus on cost management[69] Government Support and Donations - The company received government subsidies amounting to ¥3,627,801.87 during the reporting period[10] - The company made donations exceeding ¥600,000 to support COVID-19 relief efforts during the reporting period[28] Future Plans - The company aims to expand its market presence and enhance product offerings in the upcoming quarters[64] - The company plans to expand its market presence and invest in new product development to drive future growth[75] Investment Activities - The company’s investment in Stemedica project is ongoing, with discussions on subsequent investment payments based on project progress[27] - The company experienced a net investment loss of ¥8,336,310.52, worsening from a loss of ¥3,421,119.48 in the previous period[62] Financial Reporting Changes - The company is implementing new revenue recognition standards effective January 1, 2020, impacting financial reporting[96] - The first quarter report for 2020 has not been audited, indicating preliminary figures[101]